What is the enterprise value (EV) for Rocket Pharmaceuticals, Inc. (RCKT)?

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Rocket Pharmaceuticals, Inc. (RCKT)	$271.35M	$193.79M
SAB Biotherapeutics, Inc. (SABS)vs ›	$269.77M	$266.64M
Vanda Pharmaceuticals Inc. (VNDA)vs ›	$269.41M	$236.36M
TriSalus Life Sciences, Inc. (TLSI)vs ›	$266.62M	$254.76M
Fate Therapeutics, Inc. (FATE)vs ›	$266.34M	$309.58M
Treace Medical Concepts, Inc. (TMCI)vs ›	$264.03M	$324.11M
Inhibikase Therapeutics, Inc. (IKT)vs ›	$263.41M	$232.20M
Scribe Therapeutics Inc. (SCTX)vs ›	$263.36M	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$261.28M	$112.79M
Palisade Bio, Inc. (PALI)vs ›	$261.24M	$136.07M

Enterprise Value Calculation

Market Cap

$271.35M

Total Debt

$0.00

−

Cash

$77.56M

Enterprise Value

$193.79M

EV-Based Valuation Multiples

EV/EBITDA

N/A

EV/Sales

N/A

EV/FCF

N/A

Why use EV instead of Market Cap?

EV accounts for debt - an acquirer must pay or assume it
EV deducts cash - the acquirer effectively receives it
EV enables fair comparison of companies with different capital structures
EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral

Enterprise Value (EV) Formula & Definition

Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Enterprise Value (EV) FAQ

What is the enterprise value (EV) for Rocket Pharmaceuticals, Inc. (RCKT)?: The enterprise value (EV) for RCKT stock is $193.79M.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

Cranbury, NJ

202 employees

rocketpharma.com

Healthcare / Biotechnology